Identification of Lung Cancer Patients by Serum Protein Profiling Using Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

Keqi, Han; Huang, Guang; Gao, Chunfang; Wang, Xiuli; Ma, Bo; Sun, Liangqi; Wei, Zhijie

doi:10.1097/coc.0b013e318145b98b

Cited by 56 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We, on the other hand, observed decreased C3a desArg levels in breast cancer in the current study population, as well as in a subset thereof, which we analysed for validation of the 8.9 kDa marker reported by Li et al (21). Other studies have described decreased 8.9 kDa peak intensities in breast (7,38), and lung cancer (39). Moreover, Li et al observed decreased SELDI-TOF MS C3a desArg peak intensities in sera of metastatic breast cancer patients (10).…”

Section: Discussionmentioning

confidence: 57%

“…Although peak intensities of both m/z 5350 and m/z 28183 were not significantly different in expression between breast cancer and healthy control, combination with other markers evidently improved their diagnostic performance. The m/z 5350 peak cluster, though not structurally identified, has been reported earlier as significantly increased in sera of patients with lung cancer (39) and hypopharyngeal squamous cell carcinoma (46). Based on the observed mass, we hypothesise the m/z 28183 peak cluster to represent apolipoprotein A-I.…”

Section: Itih4 Fragmentsmentioning

confidence: 99%

See 1 more Smart Citation

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS

Gast¹

2009

Oncol Rep

View full text Add to dashboard Cite

Abstract. In search for novel markers for breast cancer, we aimed to identify and validate novel serum protein profiles specific for breast cancer, and assess the influence of clinical (subjects age) and pre-analytical (sample storage duration) variables on the constructed classifiers. To this end, sera of breast cancer patients (n=152) and healthy controls (n=129), randomly divided into a training and test set, were analysed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). In the training set, 14 peak clusters were found to differ significantly in expression between cases and controls. None of the peak clusters were influenced by subjects age and sample storage duration. Ten peak clusters were also found significantly discriminative in the test set. Peak clusters were structurally identified as C3a des-arginine anaphylatoxin, (tentative) inter-·-trypsin inhibitor heavy chain 4 fragments and a fibrinogen fragment. Logistic regression analyses on the training set yielded a classification model with a moderate performance on the test set, corresponding to those reported in previously performed validation studies. Most likely originating from the highly heterogeneous nature of breast cancer, selection of breast cancer subgroups for comparison with healthy controls is expected to improve results of future diagnostic SELDI-TOF MS studies.

show abstract

Section: Discussionmentioning

confidence: 57%

Section: Itih4 Fragmentsmentioning

confidence: 99%

Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS

Gast¹

2009

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Biomarkers for colon and pancreatic cancers are found in fecal samples. Techniques for biomarker discovery include genome sequencing, arrays and differential display-related methods, proteins and phosphoproteins, antibodies, electrophoretic 2D gels, and nuclear magnetic resonance spectroscopy [67].…”

Section: Future Oncotarget Related Basic Research and Therapeuticsmentioning

confidence: 99%

The pursuit of oncotargets through understanding defective cell regulation

Qiao

Shi²,

Pardee³

2010

Oncotarget

View full text Add to dashboard Cite

AbstrAct:More effective anticancer agents are essential, as has too often been demonstrated by the paucity of therapeutics which preserve life. Their discovery is very difficult. Many approaches are being applied, from testing folk medicines to automated high throughput screening of large chemical libraries. Mutations in cancer cells create dysfunctional regulatory systems. This Perspective summarizes an approach to applying defective molecular control mechanisms as oncotargets on which drug discoveries against cancer can be based.

show abstract

“…Although the fragment is directly correlated with serum coagulation in healthy individuals (2 ), its presence in samples from diseased individuals is likely due to the same mechanism. Despite numerous reports of its identification and correlation with the coagulation process, FIBA 5909 continues to be rediscovered and reported as "uncharacterized" (11 ). Remaining current with the biomarker literature has grown increasingly difficult over the years, with the growth of the field and the advent of new journals sharing the responsibility.…”

mentioning

confidence: 99%